Harvard Bioscience (HBIO) Misses Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts HBIO Hot Sheet
Price: $8.79 +1.38%
Revenue Growth %: +6.1%
Financial Fact:
Other, net: -64K
Today's EPS Names:
ATS, SICP, FTCO, More
Revenue Growth %: +6.1%
Financial Fact:
Other, net: -64K
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Harvard Bioscience (NASDAQ: HBIO) reported Q3 EPS of $0.01, $0.03 worse than the analyst estimate of $0.04. Revenue for the quarter came in at $25.4 million versus the consensus estimate of $28.02 million.
For earnings history and earnings-related data on Harvard Bioscience (HBIO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Southwest Gas (SWX) Tops Q3 EPS by 2c; Offers Guidance
- RxSight Inc. (RXST) PT Lowered to $5 at Stifel
- SmartRent (SMRT) Reports In-Line Q3 EPS
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
